SLC39A13 Knockout Cell Lines

SLC39A13 Gene Knockout Cell Lines are genetically engineered models that specifically lack the SLC39A13 gene, which encodes for a member of the solute carrier family of transporters. This gene is implicated in the uptake of essential metal ions, particularly zinc, which plays a pivotal role in various biological processes including enzymatic activity, gene expression, and cellular signaling. The SLC39A13 knockout system functions by utilizing CRISPR/Cas9 technology, which allows precise editing of the genome to delete this gene, thus enabling researchers to investigate the consequences of its loss on cellular physiology and pathology.

The key function of these cell lines is to facilitate the study of the impact of SLC39A13 deficiency on zinc homeostasis and related cellular processes. By leveraging these knockout models, scientists can explore mechanisms of disease, particularly those associated with metal ion dysregulation, such as neurodegenerative diseases, cancer, and metabolic disorders. In clinical research, understanding the role of SLC39A13 may reveal novel therapeutic targets, particularly in conditions where zinc metabolism is altered.

The unique advantages of SLC39A13 Gene Knockout Cell Lines lie in their specificity and reliability. Unlike other methods of gene inhibition, such as RNA interference, knockout models provide a complete ablation of gene expression, allowing for a clearer interpretation of phenotypic changes. This specificity is essential for robust studies in functional genomics and drug discovery. These cell lines are vital for researchers aiming to elucidate the role of zinc transporters in human health and disease, presenting a valuable tool in both academic and industrial laboratories.

Our commitment to cutting-edge genetic engineering and a deep understanding of cellular biology are hallmarks of our company's expertise, making our SLC39A13 Gene Knockout Cell Lines an unrivaled asset for those at the forefront of biomedical research.